We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Refinitiv and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from our Featured Companies page.
Avacta
Dual payload pre|CISION unveiled at EORTC-NCI-AACRHUTCHMED
ESMO: fruquintinib’s significant benefit in kidney cancerOxford BioDynamics
New EpiSwitch test for Chronic Fatigue SyndromeAvacta
Key faridox data and FAP-EXd Phase I start on the horizonScancell
FY25: Full steam ahead with iSCIB1+ANGLE
H125: Pharma Services focus attenuates industry headwindsOxford BioDynamics
PROWES: CiRT utility in guiding treatment decisionsAvacta
CB amendment creates funding solution optionalityHUTCHMED
H125: Growth prospects remain intactScancell
SCOPE’ing out iSCIB1+ in advanced melanoma